Published in AIDS on February 20, 2016
Preventing long-term tenofovir renal toxicity by pharmacokinetic assessment. AIDS (2016) 0.75
Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment. PLoS One (2016) 0.75
Changes in Urinary Biomarkers over 10 Years is Associated with Viral Suppression in a Prospective Cohort of Women Living with HIV. J Acquir Immune Defic Syndr (2016) 0.75
Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate? PLoS One (2016) 0.75
Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations. Eur J Drug Metab Pharmacokinet (2017) 0.75
A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol (2004) 42.68
The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology (1998) 12.32
A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. J Pharmacokinet Biopharm (1978) 3.47
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis (2013) 3.04
Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int (2010) 2.95
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother (2001) 2.84
Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS (2012) 2.65
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis (2011) 2.56
Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr (2010) 2.26
The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 2.19
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis (2009) 1.81
Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. Antimicrob Agents Chemother (2011) 1.77
Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest (2009) 1.43
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr (2014) 1.43
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr (2013) 1.31
Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration. J Acquir Immune Defic Syndr (2013) 1.27
Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS (2010) 1.24
Population pharmacokinetics of tenofovir in AIDS patients. J Clin Pharmacol (2008) 1.22
Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats. J Acquir Immune Defic Syndr (2009) 1.21
A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. J Infect Dis (2012) 1.17
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study. J Acquir Immune Defic Syndr (2015) 1.16
Recruitment and retention of diverse populations in antiretroviral clinical trials: practical applications from the gender, race and clinical experience study. J Womens Health (Larchmt) (2011) 1.15
Better mind the gap: addressing the shortage of HIV-positive women in clinical trials. AIDS (2010) 1.14
Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. J Acquir Immune Defic Syndr (2009) 1.10
Caring for women living with HIV: gaps in the evidence. J Int AIDS Soc (2013) 1.07
Performance of creatinine and cystatin C-based glomerular filtration rate estimating equations in a European HIV-positive cohort. AIDS (2013) 1.04
Pharmacogenetics of tenofovir treatment. Pharmacogenomics (2009) 1.03
Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther (2014) 1.00
Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure. J Infect Dis (2014) 0.96
Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients. Scand J Infect Dis (2011) 0.95
Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother (2014) 0.94
Tubulointerstitial nephropathies in HIV-infected patients over the past 15 years: a clinico-pathological study. Clin J Am Soc Nephrol (2013) 0.94
Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate - induced mitochondrial damage and increased oxido-nitrosative stress in the kidney. J Biomed Sci (2013) 0.92
Mitochondrial dysfunction and electron transport chain complex defect in a rat model of tenofovir disoproxil fumarate nephrotoxicity. J Biochem Mol Toxicol (2014) 0.91
Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events. PLoS One (2013) 0.90
Renal toxicity of long-term therapy with tenofovir in HIV-infected patients. J Pharm Pract (2012) 0.89
Subcellular renal proximal tubular mitochondrial toxicity with tenofovir treatment. Methods Mol Biol (2011) 0.87
Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. J Acquir Immune Defic Syndr (2014) 0.84
Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy. J Antimicrob Chemother (2015) 0.83
Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors? J Int AIDS Soc (2014) 0.82
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol (2005) 7.30
Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis (2009) 6.54
Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol (2003) 5.81
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis (2010) 5.35
Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst (2005) 5.29
The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med (2010) 4.89
Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet (2009) 4.78
The relative safety of ephedra compared with other herbal products. Ann Intern Med (2003) 4.65
Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med (2005) 4.57
Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol (2003) 4.28
Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr (2005) 4.02
Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol (2010) 3.85
Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol (2006) 3.85
Rapid kidney function decline and mortality risk in older adults. Arch Intern Med (2008) 3.54
Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol (2011) 3.53
Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation (2006) 3.31
Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol (2005) 3.28
Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med (2007) 3.27
A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. Arch Intern Med (2005) 3.14
Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS (2009) 3.12
The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med (2004) 3.05
Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiol Drug Saf (2005) 3.05
Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol (2012) 3.01
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
Fetuin-A and incident diabetes mellitus in older persons. JAMA (2008) 2.92
Postoperative biomarkers predict acute kidney injury and poor outcomes after pediatric cardiac surgery. J Am Soc Nephrol (2011) 2.90
The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med (2004) 2.86
Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol (2003) 2.83
Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis (2013) 2.82
Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst (2003) 2.81
Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med (2007) 2.71
Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation (2010) 2.71
CUBN is a gene locus for albuminuria. J Am Soc Nephrol (2011) 2.70
Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health (2004) 2.66
Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis (2004) 2.66
Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States. J Acquir Immune Defic Syndr (2011) 2.65
Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS (2012) 2.65
Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol (2013) 2.64
Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation (2006) 2.61
Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol (2006) 2.58
Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol (2011) 2.56
Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study. Circulation (2006) 2.50
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr (2010) 2.47
Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS (2005) 2.42
Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med (2003) 2.40
Red cell distribution width and mortality in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci (2009) 2.32
Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer (2008) 2.30
Adherence to antiretroviral therapy and its association with sexual behavior in a national sample of women with human immunodeficiency virus. Clin Infect Dis (2002) 2.29
Microalbuminuria in HIV infection. AIDS (2007) 2.28
Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation (2006) 2.27
Relationship of uric acid with progression of kidney disease. Am J Kidney Dis (2007) 2.26
Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease. J Am Soc Nephrol (2006) 2.26
Awareness of kidney disease and relationship to end-stage renal disease and mortality. Am J Med (2012) 2.24
Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Circulation (2007) 2.23
Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst (2004) 2.23
Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol (2012) 2.22
Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. Am J Public Health (2006) 2.19
Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol (2008) 2.18
Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol (2004) 2.17
Differences in medical care and disease outcomes among black and white women with heart disease. Circulation (2003) 2.16
Racial and ethnic disparities in mortality from acute lung injury. Crit Care Med (2009) 2.14
Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 2.11
Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med (2002) 2.11
Differences in kidney function and incident hypertension: the multi-ethnic study of atherosclerosis. Ann Intern Med (2008) 2.11
Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS (2007) 2.10
Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol (2012) 2.10
Uromodulin levels associate with a common UMOD variant and risk for incident CKD. J Am Soc Nephrol (2009) 2.10
Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr (2008) 2.05
Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis (2005) 2.04
Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS (2005) 2.03
Biomarkers predict progression of acute kidney injury after cardiac surgery. J Am Soc Nephrol (2012) 2.00
Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev (2010) 2.00
Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr (2007) 1.98
Urinary creatinine excretion rate and mortality in persons with coronary artery disease: the Heart and Soul Study. Circulation (2010) 1.97
The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr (2005) 1.96
Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes. J Am Soc Nephrol (2013) 1.95
Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. Clin Infect Dis (2004) 1.94
The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS (2011) 1.94
Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch Intern Med (2007) 1.94
Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. AIDS (2004) 1.94
The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr (2008) 1.94
Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol (2006) 1.92
Control of hypertension in adults with chronic kidney disease in the United States. Hypertension (2005) 1.92
Chronic kidney disease and cognitive impairment in menopausal women. Am J Kidney Dis (2005) 1.91
Cystatin C and measures of physical function in elderly adults: the Health, Aging, and Body Composition (HABC) Study. Am J Epidemiol (2006) 1.91
Improving guideline adherence: a randomized trial evaluating strategies to increase beta-blocker use in heart failure. Circulation (2003) 1.89
Early postoperative serum cystatin C predicts severe acute kidney injury following pediatric cardiac surgery. Kidney Int (2011) 1.88